Amphotericin B: all 95 studies that test it

Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy of Liposomal Amphotericin B for Patients With Invasive Mold Diseases in Liver Transplant RecipientsNot yet recruitingNCT07725874Not applicable
• Amphotericin B for Breakthrough Fungal Infections After Triazole Prophylaxis in Hematological PatientsNot yet recruitingNCT07559032Not applicable
• Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)Not yet recruitingNCT07463040Phase 3
• Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic DysfunctionNot yet recruitingNCT07337720Not applicable
• Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel DiseaseRecruitingNCT07300553Phase 2
• Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated TalaromycosisNot yet recruitingNCT06926569Not applicable
• Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)Not yet recruitingNCT06525389Phase 3
• A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary AspergillosisRecruitingNCT06447402Phase 3
• Amphotericin B for Non-HIV Cryptococcal Meningitis PatientsEnrolling by invitationNCT06178627Phase 4
• Treatment of Mucosal Bolivian LeishmaniasisRecruitingNCT04799236Phase 3
• Chronic Pulmonary Aspergillosis and Ambisome Aerosol with ItraconazoleRecruitingNCT03656081Phase 3
• CAMB/MAT2203 in Patients With Mucocutaneous CandidiasisCompletedNCT02629419Phase 2Results posted
• Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute LeukaemiaCompletedNCT01615809Phase 2Results posted
• Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic LeukemiaCompletedNCT01259713Phase 3Results posted
• Antifungal Locks to Treat Fungal-related Central Line InfectionsCompletedNCT00936910Phase 4Results posted
• Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)CompletedNCT00750737Phase 3Results posted
• Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal InfectionsCompletedNCT00418951Phase 2Results posted
• Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated MeningitisCompletedNCT00145249Phase 2Results posted
• Efficacy and Safety of Topical Amphotericin B Solution in Treatment of Resistant Tinea Capitis in Children 16 Years Old or Less we Follow up Cases Weekly up to 8 Weeks and Notice Improvement of Itching ,Scaling, and Hair Regrowth Then Fungal Culture Done to See if the Solution WorkingActive, not recruitingNCT06980493Phase 2/3
• Human Bioequivalence Study of Amphotericin B Liposome for InjectionCompletedNCT06977490Not applicable
• Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the ElderlyCompletedNCT06449040Phase 1/2
• Bioequivalence of Amphotericin B Liposome for InjectionCompletedNCT05913921Phase 1
• Pharmacokinetics and Safety of AmBisome and DKF-5122CompletedNCT05749380Phase 1
• Clinical Study of ABCD in the Treatment of Cryptococcal MeningitisStatus unknownNCT05471063Not applicable
• Olorofim Aspergillus Infection StudyCompletedNCT05101187Phase 3
• A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy SubjectsCompletedNCT04993222Phase 1
• Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study)CompletedNCT04267497Phase 1
• AmB Dose for Cryptococcal MeningitisStatus unknownNCT04140461Phase 3
• Three Induction Treatments on Cryptococcal MeningitisStatus unknownNCT04072640Early Phase 1
• Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)CompletedNCT04031833Phase 1/2
• Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.WithdrawnNCT04018417Phase 2/3
• Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed ConditionCompletedNCT03636659Phase 1
• Short Course Regimens for Treatment of PKDL (Sudan)Status unknownNCT03399955Phase 2
• Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in BangladeshCompletedNCT03311607Phase 4
• Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal MeningitisStatus unknownNCT02686853Phase 4
• Topical Liposomal Amphotericin B Gel Treatment for Cutaneous LeishmaniasisCompletedNCT02656797Phase 2
• Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN)CompletedNCT02320604Phase 4
• Amphotericin-B and Voriconazole for Pulmonary BlastomycosisTerminatedNCT02283905Phase 4
• Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).CompletedNCT02273661Phase 2
• Liposomal Amphotericin B for the Treatment of Cryptococcal MeningitisStatus unknownNCT02136030Not applicable
• Liposomal Amphotericin in Disseminated LeishmaniasisCompletedNCT02025491Phase 3
• A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary AspergillosisCompletedNCT01857479Phase 2/3
• An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy SubjectsCompletedNCT01652859Phase 1
• Single Dose Liposomal Amphotericin B for Visceral LeishmaniasisStatus unknownNCT01566552Phase 4
• SCH708980 With and Without AmBisome for Visceral LeishmaniasisWithdrawnNCT01437020Phase 1/2
• Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in BrazilTerminatedNCT01310738Phase 4
• Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant RecipientsSuspendedNCT01254708Phase 2
• Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in BangladeshCompletedNCT01122771Phase 3
• Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern AfricaCompletedNCT01067443Phase 2
• Amphotericin B to Treat Visceral Leishmaniasis in Brazilian ChildrenCompletedNCT01032187Phase 4
• Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal TransplantationStatus unknownNCT00986713Phase 4
• Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VLTerminatedNCT00832208Phase 2
• Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis PatientsStatus unknownNCT00697944Phase 4
• Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral LeishmaniasisCompletedNCT00696969Phase 3
• CRITIC - Treatment of Candidemia and Invasive CandidiasisCompletedNCT00670657Phase 4
• Single Infusion of Liposomal Amphotericin B in Indian Visceral LeishmaniasisCompletedNCT00628719Phase 3
• Antifungal Prophylaxis in Pediatric Acute LeukemiaStatus unknownNCT00624143Phase 3
• Combination Therapy in Indian Visceral LeishmaniasisCompletedNCT00523965Phase 3
• Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis TreatmentCompletedNCT00467883Phase 2
• Intermittent Liposomal Amphotericin B Primary ProphylaxisStatus unknownNCT00451711Phase 2
• Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to AntibioticsTerminatedNCT00421187Phase 4
• ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic LeukemiaTerminatedNCT00386997Phase 4
• Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azarCompletedNCT00371995Phase 2
• Combination Chemotherapy for the Treatment of Indian Kala-AzarCompletedNCT00370825Phase 2
• PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute LeukaemiaCompletedNCT00362544Phase 4
• To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment EarlyCompletedNCT00361517Phase 3
• COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive AspergillosisCompletedNCT00334412Phase 4
• PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00326157Phase 2
• Inhalation of Liposomal Amphotericin B to Prevent Invasive AspergillosisCompletedNCT00263315Phase 2/3
• Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant RecipientsTerminatedNCT00235651Phase 3
• Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged NeutropeniaTerminatedNCT00190463Phase 4
• Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome StudyCompletedNCT00177710Phase 3
• Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)CompletedNCT00177684Phase 3
• Ambisome in Liver Transplant PatientsTerminatedNCT00161356Phase 4
• Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial TreatmentCompletedNCT00158730Phase 3
• A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell TransplantationCompletedNCT00148148Phase 2
• MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)CompletedNCT00076869Phase 2
• Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for AspergillosisTerminatedNCT00047827Phase 2
• Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer PatientsCompletedNCT00003938Phase 3
• Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal InfectionCompletedNCT00003315Phase 3
• The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal MeningitisCompletedNCT00002316Phase 1
• A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal MeningitisCompletedNCT00002305Not applicable
• A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal InfectionsCompletedNCT00002277Phase 3
• A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or HistoplasmosisCompletedNCT00002159Phase 3
• Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal MeningitisCompletedNCT00002075Not applicable
• Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency SyndromeCompletedNCT00002074Not applicable
• A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal MeningitisCompletedNCT00002068Not applicable
• Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised PatientsCompletedNCT00002041Not applicable
• Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency SyndromeCompletedNCT00002019Not applicable
• Voriconazole vs. Amphotericin B in the Treatment of Invasive AspergillosisCompletedNCT00001646Phase 3
• Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver TransplantsCompletedNCT00001107Phase 4
• A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With FluconazoleCompletedNCT00001065Phase 2
• Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDSCompletedNCT00001017Phase 3
• Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal MeningitisCompletedNCT00000708Not applicable
• A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal MeningitisCompletedNCT00000639Not applicable

← Amphotericin B overview